- Gastrointestinal cancer
-
A Phase 3 Randomized Clinical Trial to Compare Efficacy and Safety between Combination Therapy and Monotherapy in Elderly Patients with Advanced Gastric Cancer (KCSG ST13-10)
-
Keun-Wook Lee, Dae Young Zang, Min-Hee Ryu, Hye Sook Han, Ki Hyang Kim, Mi-Jung Kim, Sung Ae Koh, Sung Sook Lee, Dong-Hoe Koo, Yoon Ho Ko, Byeong Seok Sohn, Jin Won Kim, Jin Hyun Park, Byung-Ho Nam, In Sil Choi
-
Cancer Res Treat. 2023;55(4):1250-1260. Published online May 25, 2023
-
DOI: https://doi.org/10.4143/crt.2023.333
-
-
 Abstract
 PDF Supplementary Material PubReader ePub
- Purpose
This study evaluated whether combination therapy is more effective than monotherapy in elderly patients with metastatic or recurrent gastric cancer (MRGC) as first-line chemotherapy.
Materials and Methods
Elderly (≥ 70 years) chemo-naïve patients with MRGC were allocated to receive either combination therapy (group A: 5-fluorouracil [5-FU]/oxaliplatin, capecitabine/oxaliplatin, capecitabine/cisplatin, or S-1/cisplatin) or monotherapy (group B: 5-FU, capecitabine, or S-1). In group A, starting doses were 80% of standard doses, and they could be escalated to 100% at the discretion of the investigator. Primary endpoint was to confirm superior overall survival (OS) of combination therapy vs. monotherapy.
Results
After 111 of the planned 238 patients were randomized, enrollment was terminated due to poor accrual. In the full-analysis population (group A [n=53] and group B [n=51]), median OS of combination therapy vs. monotherapy was 11.5 vs. 7.5 months (hazard ratio [HR], 0.86; 95% confidence interval [CI], 0.56 to 1.30; p=0.231). Median progression-free survival (PFS) was 5.6 vs. 3.7 months (HR, 0.53; 95% CI, 0.34 to 0.83; p=0.005). In subgroup analyses, patients aged 70-74 years tended to have superior OS with combination therapy (15.9 vs. 7.2 months, p=0.056). Treatment-related adverse events (TRAEs) occurred more frequently in group A vs. group B. However, among severe TRAEs (≥ grade 3), there were no TRAEs with a frequency difference of > 5%.
Conclusion
Combination therapy was associated with numerically improved OS, although statistically insignificant, and a significant PFS benefit compared with monotherapy. Although combination therapy showed more frequent TRAEs, there was no difference in the frequency of severe TRAEs.
-
Citations
Citations to this article as recorded by  - A prognostic nomogram to predict the cancer-specific survival of patients with initially diagnosed metastatic gastric cancer: a validation study in a Chinese cohort
Ziming Zhao, Erxun Dai, Bao Jin, Ping Deng, Zulihaer Salehebieke, Bin Han, Rongfan Wu, Zhaowu Yu, Jun Ren
Clinical and Translational Oncology.2024;[Epub] CrossRef
-
3,472
View
-
288
Download
-
1
Web of Science
-
1
Crossref
-
Investigating the Feasibility of Targeted Next-Generation Sequencing to Guide the Treatment of Head and Neck Squamous Cell Carcinoma
-
Sun Min Lim, Sang Hee Cho, In Gyu Hwang, Jae Woo Choi, Hyun Chang, Myung-Ju Ahn, Keon Uk Park, Ji-Won Kim, Yoon Ho Ko, Hee Kyung Ahn, Byoung Chul Cho, Byung-Ho Nam, Sang Hoon Chun, Ji Hyung Hong, Jung Hye Kwon, Jong Gwon Choi, Eun Joo Kang, Tak Yun, Keun-Wook Lee, Joo-Hang Kim, Jin Soo Kim, Hyun Woo Lee, Min Kyoung Kim, Dongmin Jung, Ji Eun Kim, Bhumsuk Keam, Hwan Jung Yun, Sangwoo Kim, Hye Ryun Kim
-
Cancer Res Treat. 2019;51(1):300-312. Published online May 9, 2018
-
DOI: https://doi.org/10.4143/crt.2018.012
-
-
Abstract
PDFSupplementary MaterialPubReaderePub
- Purpose
Head and neck squamous cell carcinoma (HNSCC) is a deadly disease in which precision medicine needs to be incorporated. We aimed to implement next-generation sequencing (NGS) in determining actionable targets to guide appropriate molecular targeted therapy in HNSCC patients.
Materials and Methods
Ninety-three tumors and matched blood samples underwent targeted sequencing of 244 genes using the Illumina HiSeq 2500 platform with an average depth of coverage of greater than 1,000×. Clinicopathological data from patients were obtained from 17 centers in Korea, and were analyzed in correlation with NGS data.
Results
Ninety-two of the 93 tumors were amenable to data analysis. TP53 was the most common mutation, occurring in 47 (51%) patients, followed by CDKN2A (n=23, 25%), CCND1 (n=22, 24%), and PIK3CA (n=19, 21%). The total mutational burden was similar between human papillomavirus (HPV)–negative vs. positive tumors, although TP53, CDKN2A and CCND1 gene alterations occurred more frequently in HPV-negative tumors. HPV-positive tumors were significantly associated with immune signature-related genes compared to HPV-negative tumors. Mutations of NOTCH1 (p=0.027), CDKN2A (p < 0.001), and TP53 (p=0.038) were significantly associated with poorer overall survival. FAT1 mutations were highly enriched in cisplatin responders, and potentially targetable alterations such as PIK3CA E545K and CDKN2A R58X were noted in 14 patients (15%).
Conclusion
We found several targetable genetic alterations, and our findings suggest that implementation of precision medicine in HNSCC is feasible. The predictive value of each targetable alteration should be assessed in a future umbrella trial using matched molecular targeted agents.
-
Citations
Citations to this article as recorded by - Personalized Biomarker-Based Umbrella Trial for Patients With Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma: KCSG HN 15-16 TRIUMPH Trial
Bhumsuk Keam, Min Hee Hong, Seong Hoon Shin, Seong Gu Heo, Ji Eun Kim, Hee Kyung Ahn, Yun-Gyoo Lee, Keon-Uk Park, Tak Yun, Keun-Wook Lee, Sung-Bae Kim, Sang-Cheol Lee, Min Kyoung Kim, Sang Hee Cho, So Yeon Oh, Sang-Gon Park, Shinwon Hwang, Byung-Ho Nam, S
Journal of Clinical Oncology.2024; 42(5): 507. CrossRef - A Phase II Trial of Nintedanib in Patients with Metastatic or Recurrent Head and Neck Squamous Cell Carcinoma: In-Depth Analysis of Nintedanib Arm from the KCSG HN 15-16 TRIUMPH Trial
Kyoo Hyun Kim, Sun Min Lim, Hee Kyung Ahn, Yun-Gyoo Lee, Keun-Wook Lee, Myung-Ju Ahn, Bhumsuk Keam, Hye Ryun Kim, Hyun Woo Lee, Ho Jung An, Jin-Soo Kim
Cancer Research and Treatment.2024; 56(1): 37. CrossRef - Extracellular vesicles as tools and targets in therapy for diseases
Mudasir A. Kumar, Sadaf K. Baba, Hana Q. Sadida, Sara Al. Marzooqi, Jayakumar Jerobin, Faisal H. Altemani, Naseh Algehainy, Mohammad A. Alanazi, Abdul-Badi Abou-Samra, Rakesh Kumar, Ammira S. Al-Shabeeb Akil, Muzafar A. Macha, Rashid Mir, Ajaz A. Bhat
Signal Transduction and Targeted Therapy.2024;[Epub] CrossRef - Impact of PIK3CA and cell cycle pathway genetic alterations on durvalumab efficacy in patients with head and neck squamous cell carcinoma: Post hoc analysis of TRIUMPH study
Dong Hyun Kim, Seung Taek Lim, Hye Ryun Kim, Eun Joo Kang, Hee Kyung Ahn, Yun-Gyoo Lee, Der Sheng Sun, Jung Hye Kwon, Sang-Cheol Lee, Hyun Woo Lee, Min Kyoung Kim, Bhumsuk Keam, Keon-Uk Park, Seong-Hoon Shin, Hwan Jung Yun
Oral Oncology.2024; 151: 106739. CrossRef - Characterization of macrophages in head and neck squamous cell carcinoma and development of MRG-based risk signature
Lei Liu, Qiang Liu
Scientific Reports.2024;[Epub] CrossRef - The Next Chapter in Cancer Diagnostics: Advances in HPV-Positive Head and Neck Cancer
Antea Krsek, Lara Baticic, Tamara Braut, Vlatka Sotosek
Biomolecules.2024; 14(8): 925. CrossRef - Biomarkers in head and neck squamous cell carcinoma: unraveling the path to precision immunotherapy
Kamal S. Saini, Sasikala Somara, Heidi C. Ko, Purva Thatai, Angela Quintana, Zachary D. Wallen, Michelle F. Green, Ravi Mehrotra, Sandra McGuigan, Lingjuan Pang, Soma Das, Kavita Yadav, Dobrica Neric, Luca Cantini, Chinmayee Joshi, Kazuya Iwamoto, Sudha D
Frontiers in Oncology.2024;[Epub] CrossRef - Massive parallel sequencing of head and neck conventional squamous cell carcinomas: A comprehensive review
Alfons Nadal, Antonio Cardesa, Abbas Agaimy, Alhadi Almangush, Alessandro Franchi, Henrik Hellquist, Ilmo Leivo, Nina Zidar, Alfio Ferlito
Virchows Archiv.2024;[Epub] CrossRef - FAT1 expression in T-cell acute lymphoblastic leukemia (T-ALL) modulates proliferation and WNT signaling
Sven Liebig, Martin Neumann, Patricia Silva, Jutta Ortiz-Tanchez, Veronika Schulze, Konstandina Isaakidis, Cornelia Schlee, Michael P. Schroeder, Thomas Beder, Luc G. T. Morris, Timothy A. Chan, Lorenz Bastian, Thomas Burmeister, Stefan Schwartz, Nicola G
Scientific Reports.2023;[Epub] CrossRef - Short-term immune-checkpoint inhibition partially rescues perturbed bone marrow hematopoiesis in mismatch-repair deficient tumors
Paula Krone, Annabell Wolff, Julia Teichmann, Johanna Maennicke, Julia Henne, Leonie Engster, Inken Salewski, Wendy Bergmann, Christian Junghanss, Claudia Maletzki
OncoImmunology.2023;[Epub] CrossRef - Genetic Mutations Associated with Inflammatory Response Caused by HPV Integration in Oropharyngeal Squamous Cell Carcinoma
Mai Atique, Isis Muniz, Fatemeh Farshadi, Michael Hier, Alex Mlynarek, Marco Macarella, Mariana Maschietto, Belinda Nicolau, Moulay A. Alaoui-Jamali, Sabrina Daniela da Silva
Biomedicines.2023; 12(1): 24. CrossRef - New Treatment Development for Larynx Preservation
Susumu Okano
Koutou (THE LARYNX JAPAN).2023; 35(2): 98. CrossRef - Current Trends in Precision Medicine and Next-Generation Sequencing in Head and Neck Cancer
Roberto N. Solis, Dustin A. Silverman, Andrew C. Birkeland
Current Treatment Options in Oncology.2022; 23(2): 254. CrossRef - EGFR Mutation and 11q13 Amplification Are Potential Predictive Biomarkers for Immunotherapy in Head and Neck Squamous Cell Carcinoma
Shengjin Dou, Lin Zhang, Chong Wang, Yanli Yao, Wen Jiang, Lulu Ye, Jiang Li, Sicheng Wu, Debin Sun, Xiaoli Gong, Rongrong Li, Guopei Zhu
Frontiers in Immunology.2022;[Epub] CrossRef - Diagnostics of HNSCC Patients: An Analysis of Cell Lines and Patient-Derived Xenograft Models for Personalized Therapeutical Medicine
Ramona Gabriela Ursu, Ionut Luchian, Costin Damian, Elena Porumb-Andrese, Nicolae Ghetu, Roxana Gabriela Cobzaru, Catalina Lunca, Carmen Ripa, Diana Costin, Igor Jelihovschi, Florin Dumitru Petrariu, Luminita Smaranda Iancu
Diagnostics.2022; 12(5): 1071. CrossRef - Unraveling most abundant mutational signatures in head and neck cancer
Michaela Plath, Johanna Gass, Mario Hlevnjak, Qiaoli Li, Bohai Feng, Xavier Pastor Hostench, Matthias Bieg, Lea Schroeder, Dana Holzinger, Marc Zapatka, Kolja Freier, Wilko Weichert, Jochen Hess, Karim Zaoui
International Journal of Cancer.2021; 148(1): 115. CrossRef - Worldwide prevalence of PI3K-AKT-mTOR pathway mutations in head and neck cancer: A systematic review and meta-analysis
Adriana Castelo de Moura, Daniele Xavier Assad, Juliana Amorim dos Santos, Isabela Porto de Toledo, Gustavo Barcelos Barra, Rogerio Moraes Castilho, Cristiane Helena Squarize, Eliete Neves Silva Guerra
Critical Reviews in Oncology/Hematology.2021; 160: 103284. CrossRef - Immuno-Oncological Biomarkers for Squamous Cell Cancer of the Head and Neck: Current State of the Art and Future Perspectives
Stijn J. De Keukeleire, Tijl Vermassen, Elien Hilgert, David Creytens, Liesbeth Ferdinande, Sylvie Rottey
Cancers.2021; 13(7): 1714. CrossRef - Comprehensive Analysis of Mutation-Based and Expressed Genes-Based Pathways in Head and Neck Squamous Cell Carcinoma
Bhumsuk Keam, Jin-Young Park, Jin-Pyo Kim, Gun-Do Kim, Yun-Suk Yu, Sang-Hee Cho, Sangwoo Kim, Hee-Kyung Ahn, Sang-Hoon Chun, Jung-Hye Kwon, Tak Yun, Ji-Won Kim, Ji-Eun Kim, Myung-Ju Ahn, Joo-Hang Kim, Hwan-Jung Yun
Processes.2021; 9(5): 792. CrossRef - Prognostic and Predictive Factors in Advanced Head and Neck Squamous Cell Carcinoma
Teresa Magnes, Sandro Wagner, Dominik Kiem, Lukas Weiss, Gabriel Rinnerthaler, Richard Greil, Thomas Melchardt
International Journal of Molecular Sciences.2021; 22(9): 4981. CrossRef - A phase II study of poziotinib in patients with recurrent and/or metastatic head and neck squamous cell carcinoma
Ji Hyun Lee, Seong Gu Heo, Beung‐Chul Ahn, Min Hee Hong, Byoung Chul Cho, Sun Min Lim, Hye Ryun Kim
Cancer Medicine.2021; 10(20): 7012. CrossRef - Therapeutic implications of activating noncanonical PIK3CA mutations in head and neck squamous cell carcinoma
Nan Jin, Bhumsuk Keam, Janice Cho, Michelle J. Lee, Hye Ryun Kim, Hayarpi Torosyan, Natalia Jura, Patrick K.S. Ng, Gordon B. Mills, Hua Li, Yan Zeng, Zohar Barbash, Gabi Tarcic, Hyunseok Kang, Julie E. Bauman, Mi-Ok Kim, Nathan K. VanLandingham, Danielle
Journal of Clinical Investigation.2021;[Epub] CrossRef - Understanding the Pattern of Oropharyngeal Cancers from North-East Romanian Patients
Ramona Ursu, Simona Giusca, Irene Spiridon, Bianca Manole, Mihai Danciu, Victor Costan, Dragos Palade, Nicolae Ghetu, Paula Toader, Mădălina Vlad, Costin Damian, Elena Porumb-Andrese, Ionut Luchian, Luminița Iancu
Applied Sciences.2021; 11(24): 12079. CrossRef - Immunologic and immunogenomic aspects of tumor progression
Andrea Ladányi, József Tímár
Seminars in Cancer Biology.2020; 60: 249. CrossRef - Prospective assessment of the clinical benefit of a tailored cancer gene set built on a next-generation sequencing platform in patients with recurrent or metastatic head and neck cancer
Thomas C. Westbrook, Ian S. Hagemann, Jessica Ley, Kevin Chen, Kevin Palka, Jingxia Liu, Ling Chen, Peter Oppelt, Douglas Adkins
Medical Oncology.2020;[Epub] CrossRef - Biological Determinants of Chemo-Radiotherapy Response in HPV-Negative Head and Neck Cancer: A Multicentric External Validation
Martijn van der Heijden, Paul B. M. Essers, Monique C. de Jong, Reinout H. de Roest, Sebastian Sanduleanu, Caroline V. M. Verhagen, Olga Hamming-Vrieze, Frank Hoebers, Philippe Lambin, Harry Bartelink, C. René Leemans, Marcel Verheij, Ruud H. Brakenhoff,
Frontiers in Oncology.2020;[Epub] CrossRef - Molecular subtypes of oropharyngeal cancer show distinct immune microenvironment related with immune checkpoint blockade response
Min Hwan Kim, Jae-Hwan Kim, Ji Min Lee, Jae Woo Choi, Dongmin Jung, Hojin Cho, Hyundeok Kang, Min Hee Hong, Su Jin Heo, Se Heon Kim, Eun Chang Choi, Da Hee Kim, Young Min Park, Sangwoo Kim, Sun Och Yoon, Yoon Woo Koh, Byoung Chul Cho, Hye Ryun Kim
British Journal of Cancer.2020; 122(11): 1649. CrossRef - Establishment and characterization of patient-derived xenografts as paraclinical models for head and neck cancer
Han Na Kang, Jae-Hwan Kim, A-Young Park, Jae Woo Choi, Sun Min Lim, Jinna Kim, Eun Joo Shin, Min Hee Hong, Kyoung-Ho Pyo, Mi Ran Yun, Dong Hwi Kim, Hanna Lee, Sun Och Yoon, Da Hee Kim, Young Min Park, Hyung Kwon Byeon, Inkyung Jung, Soonmyung Paik, Yoon W
BMC Cancer.2020;[Epub] CrossRef - Impact of genetic variants in clinical outcome of a cohort of patients with oropharyngeal squamous cell carcinoma
Ana Carolina de Carvalho, Sandra Perdomo, Wellington dos Santos, Gabriela Carvalho Fernandes, Lais Machado de Jesus, Raiany Santos Carvalho, Cristovam Scapulatempo-Neto, Gisele Caravina de Almeida, Bruna Pereira Sorroche, Lidia Maria Rebolho Batista Arant
Scientific Reports.2020;[Epub] CrossRef - Prognostic Value of CD200R1 mRNA Expression in Head and Neck Squamous Cell Carcinoma
Hyun Chang, Yun-Gyoo Lee, Yoon Ho Ko, Jang Ho Cho, Jong-Kwon Choi, Keon Uk Park, Eun Joo Kang, Keun-Wook Lee, Sun Min Lim, Jin-Soo Kim, Hyun Woo Lee, Min Kyoung Kim, In Gyu Hwang, Sangwoo Kim, Byung-Ho Nam, Hye Ryun Kim
Cancers.2020; 12(7): 1777. CrossRef - Mouse–human co-clinical trials demonstrate superior anti-tumour effects of buparlisib (BKM120) and cetuximab combination in squamous cell carcinoma of head and neck
Hye Ryun Kim, Han Na Kang, Mi Ran Yun, Kwon Young Ju, Jae Woo Choi, Dong Min Jung, Kyoung Ho Pyo, Min Hee Hong, Myoung-Ju Ahn, Jong-Mu Sun, Han Sang Kim, Jinna Kim, Jinseon Yoo, Kyu Ryung Kim, Yoon Woo Koh, Se Heon Kim, Eun Chang Choi, Sun Ock Yoon, Hyo S
British Journal of Cancer.2020; 123(12): 1720. CrossRef - Mutationssignaturen beim Kopf- und Hals-Tumor
M. Plath, J. Hess, K. Zaoui
HNO.2020; 68(12): 922. CrossRef - BAMixChecker: an automated checkup tool for matched sample pairs in NGS cohort
Hein Chun, Sangwoo Kim, Inanc Birol
Bioinformatics.2019; 35(22): 4806. CrossRef - Diagnostic Tumor Markers in Head and Neck Squamous Cell Carcinoma (HNSCC) in the Clinical Setting
Panagiota Economopoulou, Remco de Bree, Ioannis Kotsantis, Amanda Psyrri
Frontiers in Oncology.2019;[Epub] CrossRef - A Review of HPV-Related Head and Neck Cancer
Kazuhiro Kobayashi, Kenji Hisamatsu, Natsuko Suzui, Akira Hara, Hiroyuki Tomita, Tatsuhiko Miyazaki
Journal of Clinical Medicine.2018; 7(9): 241. CrossRef
-
15,005
View
-
645
Download
-
35
Web of Science
-
35
Crossref
-
Lifestyle Risk Prediction Model for Prostate Cancer in a Korean Population
-
Sung Han Kim, Sohee Kim, Jae Young Joung, Whi-An Kwon, Ho Kyung Seo, Jinsoo Chung, Byung-Ho Nam, Kang Hyun Lee
-
Cancer Res Treat. 2018;50(4):1194-1202. Published online December 21, 2017
-
DOI: https://doi.org/10.4143/crt.2017.484
-
-
Abstract
PDFSupplementary MaterialPubReaderePub
- Purpose
The use of prostate-specific antigen as a biomarker for prostate cancer (PC) has been controversial and is, therefore, not used by many countries in their national health screening programs. The biological characteristics of PC in East Asians including Koreans and Japanese are different from those in the Western populations. Potential lifestyle risk factors for PC were evaluated with the aim of developing a risk prediction model.
Materials and Methods
A total of 1,179,172 Korean men who were cancer free from 1996 to 1997, had taken a physical examination, and completed a lifestyle questionnaire, were enrolled in our study to predict their risk for PC for the next eight years, using the Cox proportional hazards model. The model’s performance was evaluated using the C-statistic and Hosmer‒Lemeshow type chi-square statistics.
Results
The risk prediction model studied age, height, body mass index, glucose levels, family history of cancer, the frequency of meat consumption, alcohol consumption, smoking status, and physical activity, which were all significant risk factors in a univariate analysis. The model performed very well (C statistic, 0.887; 95% confidence interval, 0.879 to 0.895) and estimated an elevated PC risk in patients who did not consume alcohol or smoke, compared to heavy alcohol consumers (hazard ratio [HR], 0.78) and current smokers (HR, 0.73) (p < 0.001).
Conclusion
This model can be used for identifying Korean and other East Asian men who are at a high risk for developing PC, as well as for cancer screening and developing preventive health strategies.
-
Citations
Citations to this article as recorded by - To Drink or Not to Drink? Investigating Alcohol’s Impact on Prostate Cancer Risk
Aris Kaltsas, Michael Chrisofos, Evangelos N. Symeonidis, Athanasios Zachariou, Marios Stavropoulos, Zisis Kratiras, Ilias Giannakodimos, Asterios Symeonidis, Fotios Dimitriadis, Nikolaos Sofikitis
Cancers.2024; 16(20): 3453. CrossRef - Combinations of lifestyle behaviors and cancer risk among Korean adults
Ngoc Minh Luu, Thi Tra Bui, Thi Phuong Thao Tran, Thi Huyen Trang Nguyen, Jin-Kyoung Oh
Scientific Reports.2023;[Epub] CrossRef - Cigarette smoking and prostate cancer: A systematic review
and meta-analysis of prospective cohort studies
Sarah Al-Fayez, Ashraf El-Metwally
Tobacco Induced Diseases.2023; 21(February): 1. CrossRef - Prostate cancer risk prediction based on clinical factors and prostate-specific antigen
Taewon Hwang, Hyungseok Oh, Jung Ah Lee, Eo Jin Kim
BMC Urology.2023;[Epub] CrossRef - Association Between Red and Processed Meat Consumption and Risk of Prostate Cancer: A Systematic Review and Meta-Analysis
Saeedeh Nouri-Majd, Asma Salari-Moghaddam, Azadeh Aminianfar, Bagher Larijani, Ahmad Esmaillzadeh
Frontiers in Nutrition.2022;[Epub] CrossRef - Alcohol and Prostate Cancer: Time to Draw Conclusions
Amanda J. Macke, Armen Petrosyan
Biomolecules.2022; 12(3): 375. CrossRef - Diagnostic accuracy of prostate-specific antigen below 4 ng/mL as a cutoff for diagnosing prostate cancer in a hospital setting: A systematic review and meta-analysis
Yan Jin, Jae Hung Jung, Woong Kyu Han, Eu Chang Hwang, Yoonmi Nho, Narae Lee, Ji Eun Yun, Kwang Suk Lee, Sang Hyub Lee, Hakmin Lee, Su-Yeon Yu
Investigative and Clinical Urology.2022; 63(3): 251. CrossRef - Association between Relative Preference for Vegetables and Meat and Cancer Incidence in Korean Adults: A Nationwide Population-based Retrospective Cohort Study
Ga-Eun Yie, An Na Kim, Hyun Jeong Cho, Minji Kang, Sungji Moon, Inah Kim, Kwang-Pil Ko, Jung Eun Lee, Sue K. Park
Korean Journal of Community Nutrition.2021; 26(3): 211. CrossRef - Prostate Cancer Risk Calculators for Healthy Populations: Systematic Review
Antonio Bandala-Jacques, Kevin Daniel Castellanos Esquivel, Fernanda Pérez-Hurtado, Cristobal Hernández-Silva, Nancy Reynoso-Noverón
JMIR Cancer.2021; 7(3): e30430. CrossRef - Personalized 5-Year Prostate Cancer Risk Prediction Model in Korea Based on Nationwide Representative Data
Yohwan Yeo, Dong Wook Shin, Jungkwon Lee, Kyungdo Han, Sang Hyun Park, Keun Hye Jeon, Jungeun Shin, Aesun Shin, Jinsung Park
Journal of Personalized Medicine.2021; 12(1): 2. CrossRef - Lifestyles, health habits, and prostate cancer
Tomoyuki Kawada
Journal of Cancer Research and Clinical Oncology.2020; 146(6): 1623. CrossRef - Combination possibility and deep learning model as clinical decision-aided approach for prostate cancer
Okyaz Eminaga, Omran Al-Hamad, Martin Boegemann, Bernhard Breil, Axel Semjonow
Health Informatics Journal.2020; 26(2): 945. CrossRef - Tailored Biofunctionalized Biosensor for the Label-Free Sensing of Prostate-Specific Antigen
Sachin Mishra, Eun-Seong Kim, Parshant Kumar Sharma, Zhi-Ji Wang, Sung-Hyun Yang, Ajeet Kumar Kaushik, Cong Wang, Yang Li, Nam-Young Kim
ACS Applied Bio Materials.2020; 3(11): 7821. CrossRef - A Study on Risk Factors of the Incidence of Prostate Cancer Using National Health Insurance Service: Effects of BMI on Age
Hye Sim Kim, Tae Hwa Go, Dae Ryong Kang, Jae Hung Jung, Sung Won Kwon, Sae Chul Kim, Jae Mann Song, Hyun Chul Chung, Sang Baek Koh
Journal of Health Informatics and Statistics.2019; 44(4): 410. CrossRef
-
10,008
View
-
256
Download
-
12
Web of Science
-
14
Crossref
-
Incorporating Erlotinib or Irinotecan Plus Cisplatin into Chemoradiotherapy for Stage III Non-small Cell Lung Cancer According to EGFR Mutation Status
-
Youngjoo Lee, Ji-Youn Han, Sung Ho Moon, Byung-Ho Nam, Kun Young Lim, Geon Kook Lee, Heung Tae Kim, Tak Yun, Hye Jin An, Jin Soo Lee
-
Cancer Res Treat. 2017;49(4):981-989. Published online January 6, 2017
-
DOI: https://doi.org/10.4143/crt.2016.522
-
-
Abstract
PDFSupplementary MaterialPubReaderePub
- Purpose
Concurrent chemoradiotherapy (CCRT) is the standard care for stage III non-small cell lung cancer (NSCLC) patients; however, a more effective regimen is needed to improve the outcome by better controlling occult metastases. We conducted two parallel randomized phase II studies to incorporate erlotinib or irinotecan-cisplatin (IP) into CCRT for stage III NSCLC depending on epidermal growth factor receptor (EGFR) mutation status.
Materials and Methods
Patients with EGFR-mutant tumors were randomized to receive three cycles of erlotinib first and then either CCRT with erlotinib followed by erlotinib (arm A) or CCRT with IP only (arm B). Patients with EGFR unknown or wild-type tumors were randomized to receive either three cycles of IP before (arm C) or after CCRT with IP (arm D).
Results
Seventy-three patients were screened and the study was closed early because of slow accrual after 59 patients were randomized. Overall, there were seven patients in arm A, five in arm B, 22 in arm C, and 25 in arm D. The response rate was 71.4% and 80.0% for arm A and B, and 70.0% and 73.9% for arm C and D. The median overall survival (OS) was 39.3 months versus 31.2 months for arm A and B (p=0.442), and 16.3 months versus 25.3 months for arm C and D (p=0.050). Patients with sensitive EGFR mutations had significantly longer OS than EGFR-wild patients (74.8 months vs. 25.3 months, p=0.034). There were no unexpected toxicities.
Conclusion
Combined-modality treatment by molecular diagnostics is feasible in stage III NSCLC. EGFR-mutant patients appear to be a distinct subset with longer survival.
-
Citations
Citations to this article as recorded by - Targeted treatment for unresectable EGFR mutation-positive stage III non-small cell lung cancer: Emerging evidence and future perspectives
Terufumi Kato, Ignacio Casarini, Manuel Cobo, Corinne Faivre-Finn, Fiona Hegi-Johnson, Shun Lu, Mustafa Özgüroğlu, Suresh S. Ramalingam
Lung Cancer.2024; 187: 107414. CrossRef - The ASCENT Trial: a phase 2 study of induction and consolidation afatinib and chemoradiation with or without surgery in stage III EGFR-mutant NSCLC
Allison E B Chang, Andrew J Piper-Vallillo, Raymond H Mak, Michael Lanuti, Alona Muzikansky, Julia Rotow, Pasi A Jänne, Mari Mino-Kenudson, Scott Swanson, Cameron D Wright, David Kozono, Paul Marcoux, Zofia Piotrowska, Lecia V Sequist, Henning Willers
The Oncologist.2024; 29(7): 609. CrossRef - Management of Non-Metastatic Non-Small Cell Lung Cancer (NSCLC) with Driver Gene Alterations: An Evolving Scenario
Valeria Fuorivia, Ilaria Attili, Carla Corvaja, Riccardo Asnaghi, Ambra Carnevale Schianca, Pamela Trillo Aliaga, Ester Del Signore, Gianluca Spitaleri, Antonio Passaro, Filippo de Marinis
Current Oncology.2024; 31(9): 5121. CrossRef - Comparison of treatment regimens for unresectable stage III epidermal growth factor receptor (EGFR) mutant non-small cell lung cancer
Xin Dai, Qian Xu, Lei Sheng, Xue Zhang, Miao Huang, Song Li, Kai Huang, Jiahui Chu, Jian Wang, Jisheng Li, Yanguo Liu, Jianyuan Zhou, Shulun Nie, Lian Liu
Chinese Medical Journal.2024;[Epub] CrossRef - Management of Oncogene Driven Locally Advanced Unresectable Non-small Cell Lung Cancer
Jerold Loh, Jia Li Low, Manavi Sachdeva, Peter QJ Low, Rachel Su Jen Wong, Yiqing Huang, Puey Ling Chia, Ross A Soo
Expert Review of Anticancer Therapy.2023; 23(9): 913. CrossRef - Peptide-Hydrogel Nanocomposites for Anti-Cancer Drug Delivery
Farid Hajareh Haghighi, Roya Binaymotlagh, Ilaria Fratoddi, Laura Chronopoulou, Cleofe Palocci
Gels.2023; 9(12): 953. CrossRef - Nuclear accumulation of KPNA2 impacts radioresistance through positive regulation of the PLSCR1‐STAT1 loop in lung adenocarcinoma
Wei‐Chao Liao, Tsung‐Jen Lin, Yu‐Chin Liu, Yu‐Shan Wei, Guan‐Ying Chen, Hsiang‐Pu Feng, Yi‐Feng Chang, Hsin‐Tzu Chang, Chih‐Liang Wang, Hsinag‐Cheng Chi, Chun‐I Wang, Kwang‐Huei Lin, Wei‐Ting Ou Yang, Chia‐Jung Yu
Cancer Science.2022; 113(1): 205. CrossRef - Erlotinib Versus Etoposide/Cisplatin With Radiation Therapy in Unresectable Stage III Epidermal Growth Factor Receptor Mutation-Positive Non-Small Cell Lung Cancer: A Multicenter, Randomized, Open-Label, Phase 2 Trial
Ligang Xing, Gang Wu, Luhua Wang, Jiancheng Li, Jianhua Wang, Zhiyong Yuan, Ming Chen, Yaping Xu, Xiaolong Fu, Zhengfei Zhu, You Lu, Chun Han, Tingyi Xia, Conghua Xie, Guang Li, Shenglin Ma, Bing Lu, Qin Lin, Guangying Zhu, Baolin Qu, Wanqi Zhu, Jinming Y
International Journal of Radiation Oncology*Biology*Physics.2021; 109(5): 1349. CrossRef - A systematic review and meta-analysis of treatment-related toxicities of curative and palliative radiation therapy in non-small cell lung cancer
M. Or, B. Liu, J. Lam, S. Vinod, W. Xuan, R. Yeghiaian-Alvandi, E. Hau
Scientific Reports.2021;[Epub] CrossRef - Tyrosine Kinase Inhibitor Therapy in Unresectable Locally Advanced NSCLC: Keep Holding Our Breaths or Time to Take a Breather?
Aruz Mesci, Theodoros Tsakiridis, Anand Swaminath
Journal of Thoracic Oncology.2021; 16(10): 1607. CrossRef - Experiences of patients with lung cancer receiving concurrent chemo-radiotherapy
Choi Eunsook, Park Sunhee
Clinical Journal of Nursing Care and Practice.2021; 5(1): 015. CrossRef - Recent advances and new insights in the management of early-stage epidermal growth factor receptor-mutated non-small-cell lung cancer
Miguel J Sotelo, José Luis García, Cesar Torres-Mattos, Héctor Milián, Carlos Carracedo, María Ángeles González-Ruiz, Xabier Mielgo-Rubio, Juan Carlos Trujillo-Reyes, Felipe Couñago
World Journal of Clinical Oncology.2021; 12(10): 912. CrossRef - PLGA nanoparticle-reinforced supramolecular peptide hydrogels for local delivery of multiple drugs with enhanced synergism
Can Wu, Chunlu Wang, Lu Sun, Keming Xu, Wenying Zhong
Soft Matter.2020; 16(46): 10528. CrossRef - Epidermal growth factor receptor tyrosine kinase inhibitors combined with thoracic radiotherapy or chemoradiotherapy for advanced or metastatic non-small cell lung cancer: A systematic review and meta-analysis of single-arm trials
Ruifeng Liu, Shihong Wei, Qiuning Zhang, Xueliang Zhang, Hongtao Luo, Jinhui Tian, Yi Li, Long Ge, Xiaohu Wang
Medicine.2019; 98(29): e16427. CrossRef - Role of Anti-EGFR Targeted Therapies in Stage III Locally Advanced Non-small Cell Lung Cancer: Give or Not to Give?
Sanjal Desai, Chul Kim, Irina Veytsman
Current Oncology Reports.2019;[Epub] CrossRef
-
10,286
View
-
310
Download
-
14
Web of Science
-
15
Crossref
-
What Is the Ideal Tumor Regression Grading System in Rectal Cancer Patients after Preoperative Chemoradiotherapy?
-
Soo Hee Kim, Hee Jin Chang, Dae Yong Kim, Ji Won Park, Ji Yeon Baek, Sun Young Kim, Sung Chan Park, Jae Hwan Oh, Ami Yu, Byung-Ho Nam
-
Cancer Res Treat. 2016;48(3):998-1009. Published online October 22, 2015
-
DOI: https://doi.org/10.4143/crt.2015.254
-
-
Abstract
PDFPubReaderePub
- Purpose
Tumor regression grade (TRG) is predictive of therapeutic response in rectal cancer patients after chemoradiotherapy (CRT) followed by curative resection. However, various TRG systems have been suggested, with subjective categorization, resulting in interobserver variability. This study compared the prognostic validity of four different TRG systems in order to identify the most ideal TRG system. Materials and Methods This study included 933 patients who underwent preoperative CRT and curative resection. Primary tumors alone were graded according to the American Joint Committee on Cancer (AJCC), Dworak, and Ryan TRG systems, and both primary tumors and regional lymph nodes were graded according to a modified Dworak TRG system. The ability of each TRG system to predict recurrence-free survival (RFS) and overall survival (OS) was analyzed using chisquare and C statistics.
Results
All four TRG systems were significantly predictive of both RFS and OS (p < 0.001 each), however none was a better predictor of prognosis than ypStage. Among the four TRGs, the mDworak TRG system was a better predictor of RFS and OS than the AJCC, Dworak, and Ryan TRG systems, and both the chi-square and C statistics were higher for the former, although the differences were not statistically significant. The combination of ypStage and the modified Dworak TRG better predicted RFS and OS than ypStage alone. Conclusion The modified Dworak TRG system for evaluation of entire tumors including regional lymph nodes is a better predictor of survival than current TRG systems for evaluation of the primary tumor alone.
-
Citations
Citations to this article as recorded by
-
25,910
View
-
567
Download
-
93
Web of Science
-
87
Crossref
-
A Phase II Study of Weekly Paclitaxel Plus Gemcitabine as a Second-Line Therapy in Patients with Metastatic or Recurrent Small Cell Lung Cancer
-
Tak Yun, Heung Tae Kim, Ji-Youn Han, Sung Jin Yoon, Hyae Young Kim, Byung-Ho Nam, Jin Soo Lee
-
Cancer Res Treat. 2016;48(2):465-472. Published online May 26, 2015
-
DOI: https://doi.org/10.4143/crt.2015.061
-
-
Abstract
PDFPubReaderePub
- Purpose
Paclitaxel (P) and gemcitabine (G) are clinically synergistic in small cell lung cancer (SCLC). We evaluated the efficacy of PG as a salvage treatment for SCLC patients whose disease progressed after a platinum-containing regimen.
Materials and Methods
Eligibility included histologically confirmed SCLC, one dimensionally measurable disease, Eastern Cooperative Oncology Group performance status 0-2, and progressive disease after platinum-based chemotherapy. Treatment consisted of P (80 mg/m2) and G (1,000 mg/m2) on days 1 and 8 of each cycle of 21 days until disease progression.
Results
Thirty-three patients seen between December 2005 and February 2009 were selected into this study. Thirty patients (91%) had received irinotecan-platinum, and three had received etoposide-platinum. Sixteen patients (49%) had a treatment-free interval of less than 3 months. The overall response rate was 30.3% (29.4% in sensitive relapse and 31.3% in refractory relapse). The median time to progression was 12.0 weeks and median overall survival (OS) 31.0 weeks, with a 1-year OS rate of 30.3%. Toxicities were moderate and manageable with 18.2% grade (G) 4 neutropenia, 24.2% G3 thrombocytopenia, 6.1% G3 sensory neuropathy, and 3% G3 asthenia. One patient developed febrile neutropenia.
Conclusion
Second-line paclitaxel and gemcitabine were well-tolerated and moderately active in SCLC patients previously treated with platinum-based chemotherapy.
-
Citations
Citations to this article as recorded by - Overcoming multi-drug resistance in SCLC: a synergistic approach with venetoclax and hydroxychloroquine targeting the lncRNA LYPLAL1-DT/BCL2/BECN1 pathway
Shuxin Li, Jianyi Lv, Zhihui Li, Qiuyu Zhang, Jing Lu, Xueyun Huo, Meng Guo, Xin Liu, Changlong Li, Jinghui Wang, Hanping Shi, Li Deng, Zhenwen Chen, Xiaoyan Du
Molecular Cancer.2024;[Epub] CrossRef - Impact of Nab-Paclitaxel Plus PD-1/PD-L1 Inhibitor on Chemorefractory Relapsed Small-Cell Lung Cancer
Fengchun Mu, Bingjie Fan, Haoqian Li, Wenru Qin, Chunni Wang, Bing Zou, Linlin Wang
Future Oncology.2023; 19(19): 1367. CrossRef - Iron oxide nanoparticles induce ferroptosis via the autophagic pathway by synergistic bundling with paclitaxel
Qi Nie, Wenqing Chen, Tianmei Zhang, Shangrong Ye, Zhongyu Ren, Peng Zhang, Jian Wen
Molecular Medicine Reports.2023;[Epub] CrossRef - Current Strategies for Extensive Stage Small Cell Lung Cancer Beyond First-line Therapy
Zhonglin Hao, Janeesh Sekkath Veedu
Clinical Lung Cancer.2022; 23(1): 14. CrossRef - Clinical predictors of survival in patients with relapsed/refractory small-cell lung cancer treated with checkpoint inhibitors: a German multicentric real-world analysis
Jan A. Stratmann, Radha Timalsina, Akin Atmaca, Vivian Rosery, Nikolaj Frost, Jürgen Alt, Cornelius F. Waller, Niels Reinmuth, Gernot Rohde, Felix C. Saalfeld, Aaron Becker von Rose, Fabian Acker, Lukas Aspacher, Miriam Möller, Martin Sebastian
Therapeutic Advances in Medical Oncology.2022;[Epub] CrossRef - Functionalized FcRn-targeted nanosystems for oral drug delivery: A new approach to colorectal cancer treatment
Fatima Hameedat, Nuria A. Pizarroso, Natália Teixeira, Soraia Pinto, Bruno Sarmento
European Journal of Pharmaceutical Sciences.2022; 176: 106259. CrossRef - Comparison of two regimens of weekly paclitaxel plus gemcitabine in patients with metastatic breast cancer: propensity score–matched analysis of real-world data
Chengcheng Gong, Yizhao Xie, Yannan Zhao, Yi Li, Jian Zhang, Leiping Wang, Jun Cao, Zhonghua Tao, Xichun Hu, Biyun Wang
Therapeutic Advances in Drug Safety.2022;[Epub] CrossRef - Impact of Nab-Paclitaxel Plus PD-1/PD-L1 Inhibitor Versus Traditional Chemotherapy for Retreatment Small Cell Lung Cancer Patients
Fengchun Mu, Bingjie Fan, Wenru Qin, Shijiang Wang, Bing Zou, Linlin Wang
SSRN Electronic Journal .2022;[Epub] CrossRef - FcRn expression in cancer: Mechanistic basis and therapeutic opportunities
Imke Rudnik-Jansen, Kenneth A. Howard
Journal of Controlled Release.2021; 337: 248. CrossRef - Nanoparticle Albumin Bound Paclitaxel in the Third-Line Treatment of Recurrent Small Cell Lung Cancer in Real-World Practice: A Single Center Experience
Yuchao Wang, Li Li, Chunhua Xu
Technology in Cancer Research & Treatment.2021;[Epub] CrossRef - Combination therapy with carboplatin and paclitaxel for small cell lung cancer
Atsuto Mouri, Ou Yamaguchi, Sachiko Miyauchi, Ayako Shiono, Harue Utsugi, Fuyumi Nishihara, Yoshitake Murayama, Hiroshi Kagamu, Kunihiko Kobayashi
Respiratory Investigation.2019; 57(1): 34. CrossRef - Response to and toxicity of gemcitabine for recurrent ovarian cancer according to number of previous chemotherapy regimens
Yuji Takei, Yoshifumi Takahashi, Shizuo Machida, Akiyo Taneichi, Suzuyo Takahashi, Tomomi Nagashima, Hiroyuki Morisawa, Yasushi Saga, Shigeki Matsubara, Hiroyuki Fujiwara
Journal of Obstetrics and Gynaecology Research.2017; 43(2): 358. CrossRef - Second-line treatments of small-cell lung cancers
Nathalie Baize, Isabelle Monnet, Laurent Greillier, Gilles Quere, Mallorie Kerjouan, Henri Janicot, Alain Vergnenegre, Jean Bernard Auliac, Christos Chouaid
Expert Review of Anticancer Therapy.2017; 17(11): 1033. CrossRef
-
12,510
View
-
126
Download
-
12
Web of Science
-
13
Crossref
-
Robotic Versus Laparoscopic Surgery for Rectal Cancer after Preoperative Chemoradiotherapy: Case-Matched Study of Short-Term Outcomes
-
Yong Sok Kim, Min Jung Kim, Sung Chan Park, Dae Kyung Sohn, Dae Yong Kim, Hee Jin Chang, Byung-Ho Nam, Jae Hwan Oh
-
Cancer Res Treat. 2016;48(1):225-231. Published online March 11, 2015
-
DOI: https://doi.org/10.4143/crt.2014.365
-
-
Abstract
PDFPubReaderePub
- Purpose
Robotic surgery is expected to have advantages over laparoscopic surgery; however, there are limited data regarding the feasibility of robotic surgery for rectal cancer after preoperative chemoradiotherapy (CRT). Therefore, we evaluated the short-term outcomes of robotic surgery for rectal cancer. Materials and Methods Thirty-three patients with cT3N0-2 rectal cancer after preoperative CRT who underwent robotic low anterior resection (R-LAR) between March 2010 and January 2012 were matched with 66 patients undergoing laparoscopic low anterior resection (L-LAR). Perioperative clinical outcomes and pathological data were compared between the two groups.
Results
Patient characteristics did not differ significantly different between groups. The mean operation time was 441 minutes (R-LAR) versus 277 minutes (L-LAR; p < 0.001). The open conversion rate was 6.1% in the R-LAR group and 0% in the L-LAR group (p=0.11). There were no significant differences in the time to flatus passage, length of hospital stay, and postoperative morbidity. In pathological review, the mean number of harvested lymph nodes was 22.3 in R-LAR and 21.6 in L-LAR (p=0.82). Involvement of circumferential resection margin was positive in 16.1% and 6.7%, respectively (p=0.42). Total mesorectal excision (TME) quality was complete in 97.0% in R-LAR and 91.0% in L-LAR (p=0.41). Conclusion In our study, short-term outcomes of robotic surgery for rectal cancer after CRT were similar to those of laparoscopic surgery in respect to bowel function recovery, morbidity, and TME quality. Well-designed clinical trials are needed to evaluate the functional results and longterm outcomes of robotic surgery for rectal cancer.
-
Citations
Citations to this article as recorded by - The role of robotic-assisted surgery in the management of rectal cancer: a systematic review and meta-analysis
Chenxiong Zhang, Hao Tan, Han Xu, Jiaming Ding
International Journal of Surgery.2024; 110(10): 6282. CrossRef - Robotic-Assisted versus Laparoscopic Surgery for Rectal Cancer: An Analysis of Clinical and Financial Outcomes from a Tertiary Referral Center
Jasper Max Gebhardt, Neno Werner, Andrea Stroux, Frank Förster, Ioannis Pozios, Claudia Seifarth, Christian Schineis, Benjamin Weixler, Katharina Beyer, Johannes Christian Lauscher
Journal of Clinical Medicine.2024; 13(6): 1795. CrossRef - Association of Surgical Approaches and Outcomes in Total Mesorectal Excision and Margin Status for Rectal Cancer
Muhammad Bilal Mirza, Adriana C. Gamboa, Rebecca Irlmeier, Benjamin Hopkins, Scott E. Regenbogen, Katherine A. Hrebinko, Jennifer Holder-Murray, Jason T. Wiseman, Aslam Ejaz, Paul E. Wise, Fei Ye, Kamran Idrees, Alexander T. Hawkins, Glen C. Balch, Aimal
Journal of Surgical Research.2024; 300: 494. CrossRef - Surgical outcomes of robotic, laparoscopic, and open low anterior resection after preoperative chemoradiotherapy for patients with advanced lower rectal cancer
Sukchol Lim, Yuzo Nagai, Hiroaki Nozawa, Kazushige Kawai, Kazuhito Sasaki, Koji Murono, Shigenobu Emoto, Yuichiro Yokoyama, Tsuyoshi Ozawa, Shinya Abe, Hiroyuki Anzai, Hirofumi Sonoda, Soichiro Ishihara
Surgery Today.2023; 53(1): 109. CrossRef - Operative and oncological outcomes after robotic rectal resection compared with laparoscopy: a systematic review and meta‐analysis
Julie Flynn, Jose T. Larach, Joseph C. H. Kong, Jessica Rahme, Peadar S. Waters, Satish K. Warrier, Alexander Heriot
ANZ Journal of Surgery.2023; 93(3): 510. CrossRef - Comparison of Operative Time Between Robotic and Laparoscopic Low Anterior Resection for Rectal Cancer:A Systematic Review and Meta-Analysis
Zhen Chen, Hua Yu, Huaping Wu, Pingxi Wang, Fanwei Zeng
Surgical Innovation.2023; 30(3): 390. CrossRef - Robotic Rectal Resection for Rectal Cancer in Elderly Patients: A Systematic Review and Meta-Analysis
Rossella Reddavid, Silvia Sofia, Lucia Puca, Jacopo Moro, Simona Ceraolo, Rosa Jimenez-Rodriguez, Maurizio Degiuli
Journal of Clinical Medicine.2023; 12(16): 5331. CrossRef - Short-term and long-term efficacy in robot-assisted treatment for mid and low rectal cancer: a systematic review and meta-analysis
Huiming Wu, Renkai Guo, Huiyu Li
International Journal of Colorectal Disease.2023;[Epub] CrossRef - Robotic versus laparoscopic surgery for rectal cancer after neoadjuvant chemoradiotherapy: A propensity-score matching analysis
Tzu-Chun Chen, Jin-Tung Liang
Journal of the Formosan Medical Association.2022; 121(8): 1532. CrossRef - Short‐term outcomes of robotic‐assisted surgery following neoadjuvant chemotherapy for lower rectal cancer
Hajime Morohashi, Yoshiyuki Sakamoto, Takuya Miura, Daichi Ichinohe, Shunsuke Kubota, Keisuke Yamazaki, Aika Ichisawa, Yuto Mitsuhashi, Taiichi Wakiya, Kenichi Hakamada
Asian Journal of Endoscopic Surgery.2022; 15(3): 577. CrossRef - Robotic versus Laparoscopic Low Anterior Resection for Rectal Cancer
Aba Khaled M. Farid Uddin
World Journal of Colorectal Surgery.2022; 11(3): 47. CrossRef - Oncological outcomes of robotic-assisted total mesorectal excision after neoadjuvant concurrent chemoradiotherapy in patients with rectal cancer
Po-Jung Chen, Wei-Chih Su, Tsung-Kun Chang, Yen-Cheng Chen, Ching-Chun Li, Tzu-Chieh Yin, Hsiang-Lin Tsai, Cheng-Jen Ma, Ching-Wen Huang, Jaw-Yuan Wang
Asian Journal of Surgery.2021; 44(7): 957. CrossRef - Difference in surgical outcomes of rectal cancer by study design: meta-analyses of randomized clinical trials, case-matched studies, and cohort studies
N Hoshino, T Sakamoto, K Hida, Y Takahashi, H Okada, K Obama, T Nakayama
BJS Open.2021;[Epub] CrossRef - Postoperative complications observed with robotic versus laparoscopic surgery for the treatment of rectal cancer
Chengkui Liu, Xiaoqing Li, Qingfeng Wang
Medicine.2021; 100(36): e27158. CrossRef - Robotic and robotic-assisted vs laparoscopic rectal cancer surgery: A meta-analysis of short-term and long-term results
Guojun Tong, Guiyang Zhang, Zhaozheng Zheng
Asian Journal of Surgery.2021;[Epub] CrossRef - Robotic-Assisted vs. Standard Laparoscopic Surgery for Rectal Cancer Resection: A Systematic Review and Meta-Analysis of 19,731 Patients
Kamil Safiejko, Radoslaw Tarkowski, Maciej Koselak, Marcin Juchimiuk, Aleksander Tarasik, Michal Pruc, Jacek Smereka, Lukasz Szarpak
Cancers.2021; 14(1): 180. CrossRef - Robotic versus Laparoscopic Colorectal Surgeries
Anil Heroor, Aysha Khan, Kashish Jain, Akshay Patil, Hitesh Rajendra Singhavi
Indian Journal of Colo-Rectal Surgery.2021; 4(1): 12. CrossRef - Feasibility of robot-assisted surgery in elderly patients with rectal cancer
Wei-Chih Su, Ching-Wen Huang, Cheng-Jen Ma, Po-Jung Chen, Hsiang-Lin Tsai, Tsung-Kun Chang, Yen-Cheng Chen, Ching-Chun Li, Yung-Sung Yeh, Jaw-Yuan Wang
Journal of Minimal Access Surgery.2021; 17(2): 165. CrossRef - Robotic surgery for colorectal disease: review of current port placement and future perspectives
Jong Lyul Lee, Hassan A. Alsaleem, Jin Cheon Kim
Annals of Surgical Treatment and Research.2020; 98(1): 31. CrossRef - Comparison of clinical efficacy between robotic-laparoscopic excision and traditional laparoscopy for rectal cancer
Zhen Chen, Zhuo Li Zhu, Pingxi Wang, Fanwei Zeng
Medicine.2020; 99(27): e20704. CrossRef - Oncological Outcomes of Robotic-Assisted Surgery With High Dissection and Selective Ligation Technique for Sigmoid Colon and Rectal Cancer
Tzu-Chieh Yin, Wei-Chih Su, Po-Jung Chen, Tsung-Kun Chang, Yen-Cheng Chen, Ching-Chun Li, Yi-Chien Hsieh, Hsiang-Lin Tsai, Ching-Wen Huang, Jaw-Yuan Wang
Frontiers in Oncology.2020;[Epub] CrossRef - Robotic Total Mesorectal Excision for Rectal Cancer: Current Evidences and Future Perspectives
Je-Ho Jang, Chang-Nam Kim
Annals of Coloproctology.2020; 36(5): 293. CrossRef - Systematic review analysis of robotic and transanal approaches in TME surgery- A systematic review of the current literature in regard to challenges in rectal cancer surgery
Julia K. Grass, Daniel R. Perez, Jakob R. Izbicki, Matthias Reeh
European Journal of Surgical Oncology.2019; 45(4): 498. CrossRef - Robotic Versus Conventional Laparoscopic Surgery for Colorectal Cancer: A Systematic Review and Meta‐Analysis with Trial Sequential Analysis
Ka Ting Ng, Azlan Kok Vui Tsia, Vanessa Yu Ling Chong
World Journal of Surgery.2019; 43(4): 1146. CrossRef - Robotic versus conventional laparoscopic surgery for rectal cancer: systematic review and meta-analysis
Xi-Yu Sun, Lai Xu, Jun-Yang Lu, Guan-Nan Zhang
Minimally Invasive Therapy & Allied Technologies.2019; 28(3): 135. CrossRef - Systemic review and network meta‐analysis comparing minimal surgical techniques for rectal cancer: quality of total mesorectum excision, pathological, surgical, and oncological outcomes
Emanuele Rausa, Federica Bianco, Michael E. Kelly, Alberto Aiolfi, Fausto Petrelli, Gianluca Bonitta, Giovanni Sgroi
Journal of Surgical Oncology.2019; 119(7): 987. CrossRef - TME for rectal cancer: consecutive 70 patients treated with laparoscopic and robotic technique—cumulative experience in a single centre
J. L. Mégevand, E. Lillo, M. Amboldi, L. Lenisa, A. Ambrosi, A. Rusconi
Updates in Surgery.2019; 71(2): 331. CrossRef - Completeness of total mesorectum excision of laparoscopic versus robotic surgery: a review with a meta-analysis
Marco Milone, Michele Manigrasso, Nunzio Velotti, Stefania Torino, Antonietta Vozza, Giovanni Sarnelli, Giovanni Aprea, Francesco Maione, Nicola Gennarelli, Mario Musella, Giovanni Domenico De Palma
International Journal of Colorectal Disease.2019; 34(6): 983. CrossRef - Immediate results of robotic-assisted operations in colorectal surgery
Yu. M. Stojko, A. V. Maksimenkov, A. L. Levchuk, D. A. Kolozyan
Endoskopicheskaya khirurgiya.2019; 25(2): 5. CrossRef - Short-Term Outcomes of Robotic versus Laparoscopic Total Mesorectal Excision for Rectal Cancer: A Cohort Study
Wen-Han Liu, Pei-Jing Yan, Dong-Ping Hu, Peng-Hui Jin, Yao-Chun Lv, Rong Liu, Xiong-Fei Yang, Ke-Hu Yang, Tian-Kang Guo
The American Surgeon™.2019; 85(3): 294. CrossRef - Operative time and length of stay is similar between robotic assisted and laparoscopic colon and rectal resections
Heather R. Nolan, Betsy E. Smith, Michael D. Honaker
Journal of Robotic Surgery.2018; 12(4): 659. CrossRef - Does robotic rectal cancer surgery improve the results of experienced laparoscopic surgeons? An observational single institution study comparing 168 robotic assisted with 184 laparoscopic rectal resections
Rogier M. P. H. Crolla, Paul G. Mulder, George P. van der Schelling
Surgical Endoscopy.2018; 32(11): 4562. CrossRef - Robotic total meso-rectal excision for rectal cancer: A systematic review following the publication of the ROLARR trial
Katie Jones, Mohamed G Qassem, Parv Sains, Mirza K Baig, Muhammad S Sajid
World Journal of Gastrointestinal Oncology.2018; 10(11): 449. CrossRef - Recent surgical advances in colorectal cancer excision: toward optimal outcomes
Cihangir Akyol, Mehmet Ayhan Kuzu
Colorectal Cancer.2017; 5(4): 147. CrossRef - The safety and effectiveness of robot-assisted versus laparoscopic TME in patients with rectal cancer
Xiaofei Li, Tao Wang, Liang Yao, Lidong Hu, Penghui Jin, Tiankang Guo, Kehu Yang
Medicine.2017; 96(29): e7585. CrossRef - Robotic-assisted total mesorectal excision with the single-docking technique for patients with rectal cancer
Ching-Wen Huang, Hsiang-Lin Tsai, Yung-Sung Yeh, Wei-Chih Su, Ming-Yii Huang, Chun-Ming Huang, Yu-Tang Chang, Jaw-Yuan Wang
BMC Surgery.2017;[Epub] CrossRef - Robotic Surgery for Rectal Cancer: An Update in 2015
Jung Myun Kwak, Seon Hahn Kim
Cancer Research and Treatment.2016; 48(2): 427. CrossRef - La chirurgie robotique dans le cancer du rectum
J. Coget, P. E. Colombo, A. Mourregot, D. Traoré, P. Rouanet
Oncologie.2016; 18(5): 305. CrossRef - Robot-assisted versus laparoscopic-assisted surgery for colorectal cancer: a meta-analysis
Xuan Zhang, ZhengQiang Wei, MengJun Bie, XuDong Peng, Cheng Chen
Surgical Endoscopy.2016; 30(12): 5601. CrossRef - Robotics in Colorectal Surgery
Allison Weaver, Scott Steele
F1000Research.2016; 5: 2373. CrossRef
-
12,794
View
-
134
Download
-
40
Web of Science
-
40
Crossref
-
Impact of Molecular Subtype Conversion of Breast Cancers after Neoadjuvant Chemotherapy on Clinical Outcome
-
Siew Kuan Lim, Moo Hyun Lee, In Hae Park, Ji Young You, Byung-Ho Nam, Byeong Nam Kim, Jungsil Ro, Keun Seok Lee, So-Youn Jung, Young Mee Kwon, Eun Sook Lee
-
Cancer Res Treat. 2016;48(1):133-141. Published online April 7, 2015
-
DOI: https://doi.org/10.4143/crt.2014.262
-
-
Abstract
PDFPubReaderePub
- Purpose
The aim of this study was to examine molecular subtype conversions in patients who underwent neoadjuvant chemotherapy (NAC) and analyze their clinical implications.
Materials and Methods
We included consecutive breast cancer patients who received NAC at the National Cancer Center, Korea, between August 2002 and June 2011, and had available data on estrogen receptor (ER), progesterone receptor (PR), and human epidermal growth factor 2 (HER2) receptor status prior to NAC. Molecular subtypes, hormone receptor (HR) status, and ER and PR Allred scores before and after NAC were compared, and the long-term outcomes were analyzed.
Results
Of 322 patients, 32 (9.9%) achieved a pathologic complete response after NAC. HR+/HER2– tumors tended to convert into triple negative (TN) tumors (10.3%), whereas 34.6% of TN tumors gained HR positivity to become HR+/HER2– tumors. Clinical outcomes of molecular subtype conversion groups were compared against patients who remained as HR+/HER2– throughout. The HR+/HER2– to TN group had significantly poorer recurrencefree survival (RFS) (hazard ratio, 3.54; 95% confidence interval [CI], 1.60 to 7.85) and overall survival (OS) (hazard ratio, 3.73; 95% CI, 1.34 to 10.38). Patients who remained TN throughout had the worst outcomes (for RFS: hazard ratio, 3.70; 95% CI, 1.86 to 7.36; for OS: hazard ratio, 5.85; 95% CI, 2.53 to 13.51), while those who converted from TN to HR+/HER2– showed improved comparable survival outcomes.
Conclusion
Molecular subtypes of breast cancers changed frequently after NAC, resulting in different tumor prognostication. Tumor subtyping should be repeated after NAC in patients with breast cancer.
-
Citations
Citations to this article as recorded by
-
15,280
View
-
197
Download
-
33
Web of Science
-
30
Crossref
-
The Survival and Financial Benefit of Investigator-Initiated Trials Conducted by Korean Cancer Study Group
-
Bum Jun Kim, Chi Hoon Maeng, Bhumsuk Keam, Young-Hyuck Im, Jungsil Ro, Kyung Hae Jung, Seock-Ah Im, Tae Won Kim, Jae Lyun Lee, Dae Seog Heo, Sang-We Kim, Keunchil Park, Myung-Ju Ahn, Byoung Chul Cho, Hoon-Kyo Kim, Yoon-Koo Kang, Jae Yong Cho, Hwan Jung Yun, Byung-Ho Nam, Dae Young Zang
-
Received April 30, 2024 Accepted July 8, 2024 Published online July 10, 2024
-
DOI: https://doi.org/10.4143/crt.2024.421
[Epub ahead of print]
-
-
Abstract
PDFPubReaderePub
- Purpose
The Korean Cancer Study Group (KCSG) is a nationwide cancer clinical trial group dedicated to advancing investigator-initiated trials (IITs) by conducting and supporting clinical trials. This study aims to review IITs conducted by KCSG and quantitatively evaluate the survival and financial benefits of IITs for patients.
Materials and Methods
We reviewed IITs conducted by KCSG from 1998 to 2023, analyzing progression-free survival (PFS) and overall survival (OS) gains for participants. PFS and OS benefits were calculated as the difference in median survival times between the intervention and control groups, multiplied by the number of patients in the intervention group. Financial benefits were assessed based on the cost of investigational products provided.
Results
From 1998 to 2023, KCSG conducted 310 IITs, with 133 completed and published. Of these, 21 were included in the survival analysis. The analysis revealed that 1,951 patients in the intervention groups gained a total of 2,558.4 months (213.2 years) of PFS and 2,501.6 months (208.5 years) of OS, with median gains of 1.31 months in PFS and 1.58 months in OS per patient. When analyzing only statistically significant results, PFS and OS gain per patients was 1.69 months and 3.02 months, respectively. Investigational drug cost analysis from six available IITs indicated that investigational products provided to 252 patients were valued at 10,400,077,294 won (approximately 8,046,481 US dollars), averaging about 41,270,148 won (approximately 31,930 US dollars) per patient.
Conclusion
Our findings, based on analysis of published research, suggest that IITs conducted by KCSG led to survival benefits for participants and, in some studies, may have provided financial benefits by providing investment drugs.
|
KCA
